Inside information: Nightingale Health achieves one of its business targets for this financial year by winning contracts in medical research with a total contract value of at least EUR 3.2 million
Company release, inside information
25 April 2024 at 11:50 a.m. (EEST)
Nightingale Health Plc (“Nightingale Health”) has reached one of the business targets set for the financial year 1 July 2023 – 30 June 2024 by winning contracts in medical research with a total contract value of at least EUR 3.2 million.
“The demand for our services has been strong during the financial year, resulting in achieving this business target well in time before the end of the financial year”, comments Teemu Suna, Nightingale Health's CEO and Founder.
The timeline in which the contract value from these contracts is recognized as revenue depends on the blood sample delivery and analysis schedules.
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
Certified advisor:
Oaklins Merasco Ltd, tel. +358 9 6129 670
About Nightingale Health
Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
Tags:
